Therefore, in the clinical practice with high volume of patients, screening for these hepatic co-morbidities might be considered in adolescents with persistent ALT elevation plus metabolic risk factors, such as insulin resistance, to early detect the abnormalities and prevent the progression to irreversible harmful outcomes. The gene discussed is GPT; the disease is Insulin resistance.